Given the recent emergence of appreciation of the importance of metabolic support to diseases such as AD, PD, and HD (107, 114, 122), it is evident that advanced therapeutic control of the GLP-1 super-axis could therefore generate an excellent capacity to generate whole-organism systemic therapeutic actions. This evidence concerns the gene GCG and Huntington disease.